71P MicroRNA (miRNA) a putative biomarker to better define the molecular apocrine breast cancer (MABC) subtype

Breast cancer (BC), is a heterogeneous disease, divided into molecular subtypes based on gene expression and clinical outcomes. MABC poorly diagnosed subtype, characterized by estrogen (ER), progesterone receptor (PR) negativity, HER-2-amplification in most cases; yet it overexpresses androgen (AR) activates its pathway. Its improper diagnosis demands the adoption of complementary tools to refine classification; miRNA, key players regulating cell behavior, AR, tumorigenic processes BC hold promise defining studying behavior MABC. 539 breast microarray data were downloaded from The Cancer Genome Atlas (TCGA-BRCA). Cases with available miRNA retained classified using citbcmst R package (PMID: 30289602). Differential analysis identified deregulated miRNAs DEseq2. A validation set 131 ER-neg samples was constituted tumors apart triple-negative (TN)BC previously described signature (AR, FOXA1 AR-related genes, PMID: 23663520) fresh tissue sections. Using miRCURY LNATM PCR assay, profiling done for panel 6 differentially expressed miRNAs. Finally, silico predicted target genes these assessed RT-qPCR TNBC lines after transfection mimics. TCGA indicated as separate entity signature. MiRNA-seq depicted significantly absolute value log2 fold change> 1 P-adjusted <0.05 between TNBC. We validated 78 (27 HER2-/ 51 HER2+), 53 TN samples, profiling, significant upregulation miR-2115-3p miR-187-3p compared Preliminary data, showed that overexpression downregulates (FGF2, HMGCS1, ADAM12) implicated carcinogenesis differently each models used. has unique regulate can potentially serve biomarkers effectively diagnose, prognose treat